+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      In vivo Elimination of Clonidine by Continuous Venovenous Hemofiltration in Critically Ill Patients

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Background: Clonidine is an α<sub>2</sub>-agonist that is commonly used for sedation in the intensive care unit. When patients are on continuous venovenous hemofiltration (CVVH) in the presence of kidney dysfunction, the sieving coefficient of clonidine is required to estimate how much drug is removed by CVVH. In the present study, we measured the sieving coefficient of clonidine in critically ill, ventilated patients receiving CVVH. Methods: A total of 20 samples of plasma and ultrafiltrate of 3 patients on CVVH, using a standard 1.5 m<sup>2</sup> polyacrylonitrile AN69 membrane, during continuous clonidine infusion were collected. After correction for the effect of predilution, we calculated the sieving coefficient for clonidine. Results: The mean sieving coefficient of clonidine was 0.52 (SD 0.097). Conclusion: Using a polyacrylonitrile AN69 membrane in a CVVH machine, the in vivo sieving coefficient of clonidine was 0.52.

          Related collections

          Author and article information

          Blood Purif
          Blood Purification
          S. Karger AG
          September 2020
          21 January 2020
          : 49
          : 5
          : 622-626
          aIntensive Care Unit, Deventer Hospital, Deventer, The Netherlands
          bDepartment of Clinical Geriatrics, Deventer Hospital, Deventer, The Netherlands
          cDepartment of Clinical Pharmacy, Deventer Hospital, Deventer, The Netherlands
          Author notes
          *Huub L.A. van den Oever, Intensive Care Unit, Deventer Hospital, Nico Bolkesteinlaan 75, NL–7416 SE Deventer (The Netherlands), E-Mail
          505610 Blood Purif 2020;49:622–626
          © 2020 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Tables: 1, Pages: 5
          Critical Care Nephrology – Research Article


          Comment on this article